ustekinumab vs ustekinumab-hmny (Starjemza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-12 p40 · full Ulcerative Colitis pipeline

ustekinumab · Stelara

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT02407236 · Phase 3 · completed

Randomized, double-blind, placebo-controlled, adequately powered (n=961) Phase 3 trial with clinical remission (Mayo score-based, including endoscopic subscore) as the primary endpoint, and the primary comparisons were statistically significant in the favorable direction for both induction and maintenance phases (p<0.001 to p=0.002).

Next expected readout: April 2027 · NCT07303686 (registry estimate)

Reported efficacy

Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition); Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per US Definition); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (As Per Global Definition); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (as Per US Definition): Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV) (met)

Result source: NCT02407236

ustekinumab-hmny (Starjemza)

Marketed by Bio-Thera Solutions and partners

Approved in Ulcerative Colitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointustekinumabustekinumab-hmny (Starjemza)
Clinical remission (induction)15.6% vs 5.3%+10.3 vs placebo130 mg IV · wk 8 · n 320NCT02407236
3 other results
  • 16.6% vs 6.3% 130 mg IV · wk 8 · n 320 · Phase 3 · primary NCT02407236
  • 15.5% vs 5.3% approximately 6 mg/kg IV · wk 8 · n 322 · Phase 3 · primary NCT02407236
  • 18.9% vs 6.3% approximately 6 mg/kg IV · wk 8 · n 322 · Phase 3 · primary NCT02407236
—Not reported
Clinical remission (maintenance)43.8% vs 24%+19.8 vs placebo90 mg SC every 8 weeks (q8w) · wk 44 · n 176NCT02407236
3 other results
  • 42.6% vs 24.6% 90 mg SC every 8 weeks (q8w) · wk 44 · n 176 · Phase 3 · primary NCT02407236
  • 38.4% vs 24% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · primary NCT02407236
  • 39.5% vs 24.6% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · primary NCT02407236
—Not reported
Clinical response (induction)51.3% vs 31.3%+20 vs placebo130 mg IV · wk 8 · n 320NCT02407236
1 other result
  • 61.8% vs 31.3% approximately 6 mg/kg IV · wk 8 · n 322 · Phase 3 · secondary NCT02407236
—Not reported
Endoscopic improvement (induction)—Trial running · NCT05092269—Not reported
Corticosteroid-free remission (maintenance)42% vs 23.4%+18.6 vs placebo90 mg SC every 8 weeks (q8w) · wk 44 · n 176NCT02407236
3 other results
  • 40.9% vs 24% 90 mg SC every 8 weeks (q8w) · wk 44 · n 176 · Phase 3 · secondary NCT02407236
  • 37.8% vs 23.4% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · secondary NCT02407236
  • 39% vs 24% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · secondary NCT02407236
—Not reported

Clinical remission (induction)

ustekinumab
15.6% vs 5.3%+10.3 vs placebo130 mg IV · wk 8 · n 320NCT02407236
3 other results
  • 16.6% vs 6.3% 130 mg IV · wk 8 · n 320 · Phase 3 · primary NCT02407236
  • 15.5% vs 5.3% approximately 6 mg/kg IV · wk 8 · n 322 · Phase 3 · primary NCT02407236
  • 18.9% vs 6.3% approximately 6 mg/kg IV · wk 8 · n 322 · Phase 3 · primary NCT02407236
ustekinumab-hmny (Starjemza)
—Not reported

Clinical remission (maintenance)

ustekinumab
43.8% vs 24%+19.8 vs placebo90 mg SC every 8 weeks (q8w) · wk 44 · n 176NCT02407236
3 other results
  • 42.6% vs 24.6% 90 mg SC every 8 weeks (q8w) · wk 44 · n 176 · Phase 3 · primary NCT02407236
  • 38.4% vs 24% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · primary NCT02407236
  • 39.5% vs 24.6% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · primary NCT02407236
ustekinumab-hmny (Starjemza)
—Not reported

Clinical response (induction)

ustekinumab
51.3% vs 31.3%+20 vs placebo130 mg IV · wk 8 · n 320NCT02407236
1 other result
  • 61.8% vs 31.3% approximately 6 mg/kg IV · wk 8 · n 322 · Phase 3 · secondary NCT02407236
ustekinumab-hmny (Starjemza)
—Not reported

Endoscopic improvement (induction)

ustekinumab
—Trial running · NCT05092269
ustekinumab-hmny (Starjemza)
—Not reported

Corticosteroid-free remission (maintenance)

ustekinumab
42% vs 23.4%+18.6 vs placebo90 mg SC every 8 weeks (q8w) · wk 44 · n 176NCT02407236
3 other results
  • 40.9% vs 24% 90 mg SC every 8 weeks (q8w) · wk 44 · n 176 · Phase 3 · secondary NCT02407236
  • 37.8% vs 23.4% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · secondary NCT02407236
  • 39% vs 24% 90 mg SC every 12 weeks (q12w) · wk 44 · n 172 · Phase 3 · secondary NCT02407236
ustekinumab-hmny (Starjemza)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ustekinumab-hmny (Starjemza): no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ustekinumab: 4 of 4 rows · ustekinumab-hmny (Starjemza): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricustekinumab
Dropout rate
—90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 10 more results
—90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
3.4%130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90 mg SC q12w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90 mg SC q12w to 90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
4.7%approximately 6mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
Discontinued due to AEs
—90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 10 more results
—90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0%130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90 mg SC q12w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90 mg SC q12w to 90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
—90mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.3%approximately 6mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
Serious AEs
14.3%90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 10 more results
10.5%90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
8.1%90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
12.1%90mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
8.5%90mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
7%90mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
3.7%130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
9.2%90 mg SC q12w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
9.4%90 mg SC q12w to 90 mg SC q8w
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
7.6%90mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
3.4%approximately 6mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
Most frequent reported AEs
90 mg SC q8w
nasopharyngitis 23.2% (placebo 2.8%)
colitis ulcerative 19.6% (placebo 2.5%)
alanine aminotransferase increased 12.5% (placebo 0.6%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 10 more results
90 mg SC q8w
colitis ulcerative 25.9% (placebo 2.5%)
nasopharyngitis 18.9% (placebo 2.8%)
upper respiratory tract infection 11.9% (placebo 1.3%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90 mg SC q8w
colitis ulcerative 35.1% (placebo 2.5%)
nasopharyngitis 32.4% (placebo 2.8%)
sinusitis 10.8% (placebo 0.3%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90mg SC q8w
nasopharyngitis 27.6% (placebo 2.8%)
colitis ulcerative 25.9% (placebo 2.5%)
headache 9.5% (placebo 4.4%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90mg SC every 8 weeks (q8w)
nasopharyngitis 14.8% (placebo 2.8%)
headache 10.2% (placebo 4.4%)
colitis ulcerative 9.1% (placebo 2.5%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90mg SC q8w
colitis ulcerative 14.6% (placebo 2.5%)
nasopharyngitis 12.1% (placebo 2.8%)
arthralgia 10.2% (placebo 0.9%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
130 mg IV
headache 6.9% (placebo 4.4%)
nasopharyngitis 4% (placebo 2.8%)
abdominal pain 2.5% (placebo 2.8%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90 mg SC q12w
colitis ulcerative 24.1% (placebo 2.5%)
nasopharyngitis 20.6% (placebo 2.8%)
upper respiratory tract infection 8.5% (placebo 1.3%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90 mg SC q12w to 90 mg SC q8w
colitis ulcerative 31.3% (placebo 2.5%)
nasopharyngitis 15.6% (placebo 2.8%)
arthralgia 7.8% (placebo 0.9%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
90mg SC every 12 weeks (q12w)
nasopharyngitis 18% (placebo 2.8%)
colitis ulcerative 11% (placebo 2.5%)
arthralgia 9.3% (placebo 0.9%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
approximately 6mg/kg IV
nasopharyngitis 5.6% (placebo 2.8%)
headache 4.1% (placebo 4.4%)
anaemia 2.5% (placebo 3.4%)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ustekinumab

Clinical Remission 43.8% (n=176) vs 24% (n=175) placebo @ 44wk90 mg SC every 8 weeks (q8w)
responder rate · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 77 Participants as posted
show 7 more results
42.6% (n=176) vs 24.6% (n=175) placebo @ 44wk*90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 75 Participants as posted
15.6% (n=320) vs 5.3% (n=319) placebo @ 8wk*130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 50 Participants as posted
16.6% (n=320) vs 6.3% (n=319) placebo @ 8wk*130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 53 Participants as posted
38.4% (n=172) vs 24% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 66 Participants as posted
39.5% (n=172) vs 24.6% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 68 Participants as posted
15.5% (n=322) vs 5.3% (n=319) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 50 Participants as posted
18.9% (n=322) vs 6.3% (n=319) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 61 Participants as posted
Endoscopic Healing 51.1% (n=176) vs 28.6% (n=175) placebo @ 44wk90 mg SC every 8 weeks (q8w)
event count · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 90 Participants as posted
show 3 more results
26.3% (n=320) vs 13.8% (n=319) placebo @ 8wk*130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 84 Participants as posted
43.6% (n=172) vs 28.6% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 75 Participants as posted
27% (n=322) vs 13.8% (n=319) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 87 Participants as posted
Clinical Response 71% (n=176) vs 44.6% (n=175) placebo @ 44wk90 mg SC every 8 weeks (q8w)
responder rate · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 125 Participants as posted
show 3 more results
51.3% (n=320) vs 31.3% (n=319) placebo @ 8wk*130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 164 Participants as posted
68% (n=172) vs 44.6% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 117 Participants as posted
61.8% (n=322) vs 31.3% (n=319) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 199 Participants as posted
IBDQ 5.5 vs -7 placebo score @ 20wk90 mg SC every 8 weeks (q8w)
absolute change · score
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 5 more results
3.9 vs -15.1 placebo score @ 44wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
33.4 vs 16.1 placebo score @ 8wk130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.8 vs -7 placebo score @ 20wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-3 vs -15.1 placebo score @ 44wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
35 vs 16.1 placebo score @ 8wkapproximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
Corticosteroid-free Clinical Remission 42% (n=176) vs 23.4% (n=175) placebo @ 44wk90 mg SC every 8 weeks (q8w)
responder rate · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 74 Participants as posted
show 3 more results
40.9% (n=176) vs 24% (n=175) placebo @ 44wk*90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 72 Participants as posted
37.8% (n=172) vs 23.4% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 65 Participants as posted
39% (n=172) vs 24% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 67 Participants as posted
Sustained Clinical Remission 57.9% (n=38) vs 37.8% (n=45) placebo @ 44wk90 mg SC every 8 weeks (q8w)
responder rate · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 22 Participants as posted
show 3 more results
61.4% (n=44) vs 33.3% (n=48) placebo @ 44wk*90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 27 Participants as posted
65% (n=40) vs 37.8% (n=45) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 26 Participants as posted
61.5% (n=52) vs 33.3% (n=48) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 32 Participants as posted
Mucosal Healing 45.9% (n=172) vs 24.1% (n=170) placebo @ 44wk90 mg SC every 8 weeks (q8w)
event count · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 79 Participants as posted
show 3 more results
20.3% (n=316) vs 8.9% (n=316) placebo @ 8wk*130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 64 Participants as posted
38.8% (n=170) vs 24.1% (n=170) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 66 Participants as posted
18.4% (n=315) vs 8.9% (n=316) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 58 Participants as posted
Symptomatic Remission 67.6% (n=176) vs 45.1% (n=175) placebo @ 44wk90 mg SC every 8 weeks (q8w)
responder rate · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 119 Participants as posted
show 3 more results
41.3% (n=320) vs 22.6% (n=319) placebo @ 8wk*130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 132 Participants as posted
62.2% (n=172) vs 45.1% (n=175) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 107 Participants as posted
44.7% (n=322) vs 22.6% (n=319) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 144 Participants as posted
Total Mayo -0.5 vs 1.6 placebo score @ 44wk90 mg SC every 8 weeks (q8w)
absolute change · score
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 5 more results
-5.6 vs -3.3 placebo score @ 44wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-3.2 vs -1.8 placebo score @ 8wk130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.1 vs 1.6 placebo score @ 44wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-5 vs -3.3 placebo score @ 44wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-3.5 vs -1.8 placebo score @ 8wkapproximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
Partial Mayo -0.1 vs -0.2 placebo score @ 4wk90 mg SC every 8 weeks (q8w)
absolute change · score
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
show 49 more results
-0.2 vs -0.1 placebo score @ 8wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.2 vs 0.1 placebo score @ 12wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.3 vs 0.3 placebo score @ 16wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.2 vs 0.6 placebo score @ 20wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.3 vs 0.9 placebo score @ 24wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.2 vs 1 placebo score @ 28wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.2 vs 1.1 placebo score @ 32wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.2 vs 1.2 placebo score @ 36wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.2 vs 1.3 placebo score @ 40wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0 vs 1.5 placebo score @ 44wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.4 vs -4.2 placebo score @ 4wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -4.1 placebo score @ 8wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -3.9 placebo score @ 12wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.6 vs -3.7 placebo score @ 16wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -3.4 placebo score @ 20wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -3.1 placebo score @ 24wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.4 vs -3 placebo score @ 28wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -2.9 placebo score @ 32wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -2.8 placebo score @ 36wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -2.7 placebo score @ 40wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.3 vs -2.5 placebo score @ 44wk90 mg SC every 8 weeks (q8w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-1.5 vs -1 placebo score @ 2wk130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-2.1 vs -1.4 placebo score @ 4wk130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-2.6 vs -1.5 placebo score @ 8wk130 mg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.3 vs -0.2 placebo score @ 4wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.3 vs -0.1 placebo score @ 8wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0 vs 0.1 placebo score @ 12wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.1 vs 0.3 placebo score @ 16wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.1 vs 0.6 placebo score @ 20wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0 vs 0.9 placebo score @ 24wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-0.1 vs 1 placebo score @ 28wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.1 vs 1.1 placebo score @ 32wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.2 vs 1.2 placebo score @ 36wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.3 vs 1.3 placebo score @ 40wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
0.3 vs 1.5 placebo score @ 44wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -4.2 placebo score @ 4wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.5 vs -4.1 placebo score @ 8wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.2 vs -3.9 placebo score @ 12wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.3 vs -3.7 placebo score @ 16wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.3 vs -3.4 placebo score @ 20wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.2 vs -3.1 placebo score @ 24wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.3 vs -3 placebo score @ 28wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4.1 vs -2.9 placebo score @ 32wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-4 vs -2.8 placebo score @ 36wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-3.9 vs -2.7 placebo score @ 40wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-3.9 vs -2.5 placebo score @ 44wk90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-1.6 vs -1 placebo score @ 2wkapproximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-2.5 vs -1.4 placebo score @ 4wkapproximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
-2.9 vs -1.5 placebo score @ 8wkapproximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3
IBDQ 61.3% (n=320) vs 37% (n=319) placebo @ 8wk130 mg IV
responder rate · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 196 Participants as posted
show 1 more result
62.1% (n=322) vs 37% (n=319) placebo @ 8wk*approximately 6 mg/kg IV
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 200 Participants as posted
Sustained Endoscopic Healing 64.9% (n=57) vs 35.2% (n=71) placebo @ 44wk90 mg SC every 8 weeks (q8w)
event count · % of participants
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 37 Participants as posted
show 1 more result
60.3% (n=68) vs 35.2% (n=71) placebo @ 44wk*90 mg SC every 12 weeks (q12w)
NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 · converted to % from 41 Participants as posted

Crohn's Disease

Shared mechanism: IL-12 p40 · full Crohn's Disease pipeline

ustekinumab · Stelara

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT01369329 · Phase 3 · completed

Randomized, quadruple-blinded, placebo-controlled, adequately powered (n~741) Phase 3 trial with a clinical primary endpoint (CDAI-based response), and the primary comparison for both active doses reached statistical significance in the favorable direction versus placebo, satisfying the 'strong' definition.

Next expected readout: December 2026 · NCT06520397 (registry estimate)

Reported efficacy

Number of Participants With Clinical Remission at Week 44: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w) (met)

Result source: NCT01369355

ustekinumab-hmny (Starjemza)

Marketed by Bio-Thera Solutions and partners

Approved in Crohn's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointustekinumabustekinumab-hmny (Starjemza)
Clinical remission (induction)15.9% vs 7.3%+8.6 vs placebo130 mg · wk 8 · n 245NCT01369329
15 other results
  • 30.6% vs 19.6% 130 mg · wk 8 · n 209 · Phase 3 · secondary NCT01369342
  • 20.9% vs 7.3% ~6 mg/kg · wk 8 · n 249 · Phase 3 · secondary NCT01369329
  • 40.2% vs 19.6% ~6 mg/kg · wk 8 · n 209 · Phase 3 · secondary NCT01369342
  • 35.8% vs 38.9% q4w · wk 8 · n 53 · Phase 3 · secondary NCT04245215
  • 18.3% vs 10.6% 6 mg/kg IV · wk 8 · n 131 · Phase 2 · secondary NCT00771667
  • 12.2% vs 10.6% 6 mg/kg IV · wk 6 · n 131 · Phase 2 · secondary NCT00771667
  • 18.2% vs 10.6% 3 mg/kg IV · wk 8 · n 132 · Phase 2 · secondary NCT00771667
  • 15.9% vs 10.6% 3 mg/kg IV · wk 6 · n 132 · Phase 2 · secondary NCT00771667
  • 17.6% vs 10.6% 1 mg/kg IV · wk 8 · n 131 · Phase 2 · secondary NCT00771667
  • 16% vs 10.6% 1 mg/kg IV · wk 6 · n 131 · Phase 2 · secondary NCT00771667
  • 24% vs 11.1% 90 mg SC · wk 8 · n 25 · Phase 2 · secondary NCT00265122
  • 26.9% vs 11.1% 4.5 mg/kg IV · wk 8 · n 26 · Phase 2 · secondary NCT00265122
  • 30% vs 14.6% Low Dose · wk 12 · n 50 · Phase 2 · secondary NCT02877134
  • 18.4% vs 14.6% Middle Dose · wk 12 · n 49 · Phase 2 · secondary NCT02877134
  • 22.4% vs 14.6% High Dose · wk 12 · n 49 · Phase 2 · secondary NCT02877134
—Not reported
Endoscopic response (induction)—Not posted · NCT05299931—Not reported
Clinical remission (maintenance)53.1% vs 35.9%+17.2 vs placebo90 mg SC q8w · wk 44 · n 128NCT01369355
6 other results
  • 48.8% vs 35.9% 90 mg SC Q12W · wk 44 · n 129 · Phase 3 · primary NCT01369355
  • 66.7% vs 45.6% 90 mg SC q8w · wk 44 · n 78 · Phase 3 · secondary NCT01369355
  • 41.1% vs 26.2% 90 mg SC q8w · wk 44 · n 56 · Phase 3 · secondary NCT01369355
  • 56.4% vs 45.6% 90 mg SC Q12W · wk 44 · n 78 · Phase 3 · secondary NCT01369355
  • 38.6% vs 26.2% 90 mg SC Q12W · wk 44 · n 57 · Phase 3 · secondary NCT01369355
  • 30.8% vs 36% q4w · wk 48 · n 52 · Phase 3 · secondary NCT04245215
—Not reported
Endoscopic response (maintenance)23.5% vs 16%vs Ustekinumabq4w · wk 48 · n 51NCT04245215—Not reported

Clinical remission (induction)

ustekinumab
15.9% vs 7.3%+8.6 vs placebo130 mg · wk 8 · n 245NCT01369329
15 other results
  • 30.6% vs 19.6% 130 mg · wk 8 · n 209 · Phase 3 · secondary NCT01369342
  • 20.9% vs 7.3% ~6 mg/kg · wk 8 · n 249 · Phase 3 · secondary NCT01369329
  • 40.2% vs 19.6% ~6 mg/kg · wk 8 · n 209 · Phase 3 · secondary NCT01369342
  • 35.8% vs 38.9% q4w · wk 8 · n 53 · Phase 3 · secondary NCT04245215
  • 18.3% vs 10.6% 6 mg/kg IV · wk 8 · n 131 · Phase 2 · secondary NCT00771667
  • 12.2% vs 10.6% 6 mg/kg IV · wk 6 · n 131 · Phase 2 · secondary NCT00771667
  • 18.2% vs 10.6% 3 mg/kg IV · wk 8 · n 132 · Phase 2 · secondary NCT00771667
  • 15.9% vs 10.6% 3 mg/kg IV · wk 6 · n 132 · Phase 2 · secondary NCT00771667
  • 17.6% vs 10.6% 1 mg/kg IV · wk 8 · n 131 · Phase 2 · secondary NCT00771667
  • 16% vs 10.6% 1 mg/kg IV · wk 6 · n 131 · Phase 2 · secondary NCT00771667
  • 24% vs 11.1% 90 mg SC · wk 8 · n 25 · Phase 2 · secondary NCT00265122
  • 26.9% vs 11.1% 4.5 mg/kg IV · wk 8 · n 26 · Phase 2 · secondary NCT00265122
  • 30% vs 14.6% Low Dose · wk 12 · n 50 · Phase 2 · secondary NCT02877134
  • 18.4% vs 14.6% Middle Dose · wk 12 · n 49 · Phase 2 · secondary NCT02877134
  • 22.4% vs 14.6% High Dose · wk 12 · n 49 · Phase 2 · secondary NCT02877134
ustekinumab-hmny (Starjemza)
—Not reported

Endoscopic response (induction)

ustekinumab
—Not posted · NCT05299931
ustekinumab-hmny (Starjemza)
—Not reported

Clinical remission (maintenance)

ustekinumab
53.1% vs 35.9%+17.2 vs placebo90 mg SC q8w · wk 44 · n 128NCT01369355
6 other results
  • 48.8% vs 35.9% 90 mg SC Q12W · wk 44 · n 129 · Phase 3 · primary NCT01369355
  • 66.7% vs 45.6% 90 mg SC q8w · wk 44 · n 78 · Phase 3 · secondary NCT01369355
  • 41.1% vs 26.2% 90 mg SC q8w · wk 44 · n 56 · Phase 3 · secondary NCT01369355
  • 56.4% vs 45.6% 90 mg SC Q12W · wk 44 · n 78 · Phase 3 · secondary NCT01369355
  • 38.6% vs 26.2% 90 mg SC Q12W · wk 44 · n 57 · Phase 3 · secondary NCT01369355
  • 30.8% vs 36% q4w · wk 48 · n 52 · Phase 3 · secondary NCT04245215
ustekinumab-hmny (Starjemza)
—Not reported

Endoscopic response (maintenance)

ustekinumab
23.5% vs 16%vs Ustekinumabq4w · wk 48 · n 51NCT04245215
ustekinumab-hmny (Starjemza)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ustekinumab-hmny (Starjemza): no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ustekinumab: 4 of 4 rows · ustekinumab-hmny (Starjemza): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricustekinumab
Dropout rate
4.3%130 mga
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
show 37 more results
5.4%~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
4.2%130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
1.4%~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—130 mg IV / 90 mg SC Q12W
NCT01369355 · Phase 3
—90 mg SC Q12W
NCT01369355 · Phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—90 mg SC Q12W
NCT01369355 · Phase 3
—90 mg SC Q12W/Q8W
NCT01369355 · Phase 3
31.5%q4w
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3
24.1%IV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
28%q8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
—Extension Period: Routine Care
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Extension Period: Treat to Target
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Maintenance Period: Routine Care
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Maintenance Period: Treat to Targe
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4%IV
NCT04673357 · Phase 3
—SC q12w
NCT04673357 · Phase 3
—SC q8w
NCT04673357 · Phase 3
34.2%Part I: JNJ-64304500
NCT02877134 · Phase 2 · registry result, not featured evidence
—High Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—Low Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—Middle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
20.4%High Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
30%Low Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
14.3%Middle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence
—90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence
6.1%6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
9.1%3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
7.6%1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
8%90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence
7.1%90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence
7.7%4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence
0%4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—130 mga
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
show 37 more results
—~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
—130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
—~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—130 mg IV / 90 mg SC Q12W
NCT01369355 · Phase 3
—90 mg SC Q12W
NCT01369355 · Phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—90 mg SC Q8W
NCT01369355 · Phase 3
—90 mg SC Q12W
NCT01369355 · Phase 3
—90 mg SC Q12W/Q8W
NCT01369355 · Phase 3
—q4w
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—IV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
—q8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
—Extension Period: Routine Care
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Extension Period: Treat to Target
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Maintenance Period: Routine Care
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Maintenance Period: Treat to Targe
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3%IV
NCT04673357 · Phase 3
—SC q12w
NCT04673357 · Phase 3
—SC q8w
NCT04673357 · Phase 3
—Part I: JNJ-64304500
NCT02877134 · Phase 2 · registry result, not featured evidence
—High Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—Low Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—Middle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—High Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—Low Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—Middle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
—90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence
—90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence
0.8%6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
3%3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
1.5%1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
—90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence
—90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence
—4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence
—4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence
Serious AEs
5.5%130 mga
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
show 37 more results
6.9%~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
4.6%130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
4.3%~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
28%90 mg SC Q8W
NCT01369355 · Phase 3
9.9%90 mg SC Q8W
NCT01369355 · Phase 3
16.5%130 mg IV / 90 mg SC Q12W
NCT01369355 · Phase 3
31.9%90 mg SC Q12W
NCT01369355 · Phase 3
20.7%90 mg SC Q8W
NCT01369355 · Phase 3
16.2%90 mg SC Q8W
NCT01369355 · Phase 3
12.1%90 mg SC Q12W
NCT01369355 · Phase 3
17.2%90 mg SC Q12W/Q8W
NCT01369355 · Phase 3
16.7%q4w
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8.3%IV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
12.1%q8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
13.1%Extension Period: Routine Care
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.3%Extension Period: Treat to Target
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
13.1%Maintenance Period: Routine Care
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
11.9%Maintenance Period: Treat to Targe
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3%IV
NCT04673357 · Phase 3
12.2%SC q12w
NCT04673357 · Phase 3
14.6%SC q8w
NCT04673357 · Phase 3
11%Part I: JNJ-64304500
NCT02877134 · Phase 2 · registry result, not featured evidence
20.8%High Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
9.5%Low Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
18.5%Middle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
12.2%High Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
6%Low Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
0%Middle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
20.2%90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence
12.5%90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence
6.9%6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
6%3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
4.6%1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence
4%90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence
14.3%90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence
11.1%4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence
15.4%4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
130 mga
arthralgia 11% (placebo 7.5%)
headache 7.8% (placebo 8.7%)
nausea 7.8% (placebo 7.1%)
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
show 37 more results
~6 mg/kg
headache 7.7% (placebo 8.7%)
arthralgia 5.8% (placebo 7.5%)
nausea 5.8% (placebo 7.1%)
NCT01369329 · Phase 3 · Crohn's Disease · phase 3
130 mg
headache 9.3% (placebo 6.6%)
nasopharyngitis 4.6% (placebo 4.7%)
nausea 3.2% (placebo 2.4%)
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
~6 mg/kg
nasopharyngitis 6.6% (placebo 4.7%)
nausea 5.2% (placebo 2.4%)
pyrexia 5.2% (placebo 4.7%)
NCT01369342 · Phase 3 · Crohn's Disease · phase 3
90 mg SC Q8W
nasopharyngitis 28.2% (placebo 12.2%)
crohn's disease 22.6% (placebo 10.6%)
abdominal pain 19.2% (placebo 12.2%)
NCT01369355 · Phase 3
90 mg SC Q8W
arthralgia 13.7% (placebo 18.7%)
headache 11.5% (placebo 13%)
nasopharyngitis 10.7% (placebo 12.2%)
NCT01369355 · Phase 3
130 mg IV / 90 mg SC Q12W
nasopharyngitis 11.2% (placebo 12.2%)
arthralgia 10.2% (placebo 18.7%)
upper respiratory tract infection 8.8% (placebo 5.7%)
NCT01369355 · Phase 3
90 mg SC Q12W
nasopharyngitis 25.4% (placebo 12.2%)
crohn's disease 20.7% (placebo 10.6%)
upper respiratory tract infection 18.8% (placebo 5.7%)
NCT01369355 · Phase 3
90 mg SC Q8W
arthralgia 10.3% (placebo 18.7%)
back pain 10.3% (placebo 1.6%)
abdominal pain upper 6.9% (placebo 4.1%)
NCT01369355 · Phase 3
90 mg SC Q8W
nasopharyngitis 10.9% (placebo 12.2%)
arthralgia 10.3% (placebo 18.7%)
nausea 9.7% (placebo 9.8%)
NCT01369355 · Phase 3
90 mg SC Q12W
arthralgia 16.7% (placebo 18.7%)
nasopharyngitis 12.9% (placebo 12.2%)
headache 11.4% (placebo 13%)
NCT01369355 · Phase 3
90 mg SC Q12W/Q8W
abdominal pain 17.2% (placebo 12.2%)
arthralgia 17.2% (placebo 18.7%)
nasopharyngitis 13.8% (placebo 12.2%)
NCT01369355 · Phase 3
q4w
respiratory infection 38.9%
musculoskeletal and connective tissue disorders 33.3%
abdominal pain 18.5%
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IV re-induction
crohn's disease 21.3%
covid-19 11.1%
headache 7.4%
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
q8w SC maintenance
crohn's disease 27.1%
covid-19 15%
cough 5.6%
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
nasopharyngitis 19.9%
headache 15.9%
arthralgia 14.8%
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
arthralgia 16.3%
abdominal pain 15.6%
nasopharyngitis 15.6%
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 13.1%
crohn's disease 9.5%
headache 9.5%
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 13.2%
pyrexia 11.4%
arthralgia 11%
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IV
upper respiratory tract infection 12.9%
anaemia 8.9%
headache 6.9%
NCT04673357 · Phase 3
SC q12w
crohn's disease 32.7%
upper respiratory tract infection 32.7%
anaemia 14.3%
NCT04673357 · Phase 3
SC q8w
crohn's disease 37.5%
covid-19 16.7%
upper respiratory tract infection 14.6%
NCT04673357 · Phase 3
anaemia 12.3% (placebo 4.2%)
headache 11% (placebo 6.9%)
lymphocyte count decreased 9.6% (placebo 2.8%)
NCT02877134 · Phase 2 · registry result, not featured evidence
High Dose
back pain 8.3% (placebo 0%)
crohn's disease 8.3% (placebo 5.6%)
pyrexia 8.3% (placebo 1.4%)
NCT02877134 · Phase 2 · registry result, not featured evidence
Low Dose
rash 9.5% (placebo 0%)
abdominal pain 4.8% (placebo 4.2%)
back pain 4.8% (placebo 0%)
NCT02877134 · Phase 2 · registry result, not featured evidence
Middle Dose
crohn's disease 14.8% (placebo 5.6%)
anaemia 11.1% (placebo 4.2%)
nasopharyngitis 11.1% (placebo 4.2%)
NCT02877134 · Phase 2 · registry result, not featured evidence
High Dose
rhinitis 10.2% (placebo 0%)
headache 8.2% (placebo 6.9%)
nasopharyngitis 8.2% (placebo 4.2%)
NCT02877134 · Phase 2 · registry result, not featured evidence
Low Dose
anaemia 12% (placebo 4.2%)
crohn's disease 8% (placebo 5.6%)
nasopharyngitis 6% (placebo 4.2%)
NCT02877134 · Phase 2 · registry result, not featured evidence
Middle Dose
anaemia 14.3% (placebo 4.2%)
crohn's disease 14.3% (placebo 5.6%)
headache 8.2% (placebo 6.9%)
NCT02877134 · Phase 2 · registry result, not featured evidence
90 mg SC
crohn's disease 9.2% (placebo 6.1%)
headache 7.3% (placebo 6.1%)
abdominal pain 6.4% (placebo 6.8%)
NCT00771667 · Phase 2 · registry result, not featured evidence
90 mg SC
crohn's disease 9.7% (placebo 6.1%)
nausea 9.7% (placebo 8.3%)
upper respiratory tract infection 8.3% (placebo 0%)
NCT00771667 · Phase 2 · registry result, not featured evidence
6 mg/kg IV
headache 9.9% (placebo 6.1%)
nasopharyngitis 6.1% (placebo 4.5%)
nausea 6.1% (placebo 8.3%)
NCT00771667 · Phase 2 · registry result, not featured evidence
3 mg/kg IV
headache 6.8% (placebo 6.1%)
abdominal pain 6% (placebo 6.8%)
arthralgia 6% (placebo 3%)
NCT00771667 · Phase 2 · registry result, not featured evidence
1 mg/kg IV
nausea 6.9% (placebo 8.3%)
arthralgia 6.2% (placebo 3%)
headache 6.2% (placebo 6.1%)
NCT00771667 · Phase 2 · registry result, not featured evidence
90 mg SC
headache 24% (placebo 15.8%)
arthralgia 20% (placebo 15.8%)
upper respiratory tract infection 20% (placebo 15.8%)
NCT00265122 · Phase 2 · registry result, not featured evidence
90 mg SC
crohn's disease 28.6% (placebo 21.1%)
headache 21.4% (placebo 15.8%)
nausea 21.4% (placebo 10.5%)
NCT00265122 · Phase 2 · registry result, not featured evidence
4.5 mg/kg IV
crohn's disease 25.9% (placebo 21.1%)
abdominal pain 18.5% (placebo 0%)
headache 14.8% (placebo 15.8%)
NCT00265122 · Phase 2 · registry result, not featured evidence
4.5 mg/kg IV
crohn's disease 30.8% (placebo 21.1%)
gastroenteritis viral 23.1% (placebo 10.5%)
headache 23.1% (placebo 15.8%)
NCT00265122 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 27 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ustekinumab

Clinical Response 59.4% (n=128) vs 44.3% (n=131) placebo @ 44wk90 mg SC q8w
responder rate · % of participants
NCT01369355 · Phase 3 · converted to % from 76 participants as posted
show 21 more results
69.4% (n=72) vs 42.5% (n=73) placebo @ 22wk*90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 50 Participants as posted
48% (n=25) vs 50% (n=26) placebo @ 8wk*90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence · converted to % from 12 participants as posted
34.3% (n=245) vs 21.5% (n=247) placebo @ 6wk*130 mg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 84 participants as posted
33.5% (n=245) vs 20.2% (n=247) placebo @ 8wk*130 mg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 82 participants as posted
51.7% (n=209) vs 28.7% (n=209) placebo @ 6wk*130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 108 participants as posted
47.4% (n=209) vs 32.1% (n=209) placebo @ 8wk*130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 99 participants as posted
58.1% (n=129) vs 44.3% (n=131) placebo @ 44wk*90 mg SC Q12W
NCT01369355 · Phase 3 · converted to % from 75 participants as posted
39.7% (n=131) vs 23.5% (n=132) placebo @ 6wk*6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 52 Participants as posted
30.5% (n=131) vs 16.7% (n=132) placebo @ 4wk*6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 40 Participants as posted
43.5% (n=131) vs 17.4% (n=132) placebo @ 8wk*6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 57 Participants as posted
50% (n=26) vs 50% (n=26) placebo @ 8wk*4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence · converted to % from 13 participants as posted
34.1% (n=132) vs 23.5% (n=132) placebo @ 6wk*3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 45 Participants as posted
37.1% (n=132) vs 16.7% (n=132) placebo @ 4wk*3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 49 Participants as posted
31.8% (n=132) vs 17.4% (n=132) placebo @ 8wk*3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 42 Participants as posted
36.6% (n=131) vs 23.5% (n=132) placebo @ 6wk*1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 48 Participants as posted
27.5% (n=131) vs 16.7% (n=132) placebo @ 4wk*1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 36 Participants as posted
32.1% (n=131) vs 17.4% (n=132) placebo @ 8wk*1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 42 Participants as posted
33.7% (n=249) vs 21.5% (n=247) placebo @ 6wk*~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 84 participants as posted
37.8% (n=249) vs 20.2% (n=247) placebo @ 8wk*~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 94 participants as posted
55.5% (n=209) vs 28.7% (n=209) placebo @ 6wk*~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 116 participants as posted
57.9% (n=209) vs 32.1% (n=209) placebo @ 8wk*~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 121 participants as posted
Clinical Remission 53.1% (n=128) vs 35.9% (n=131) placebo @ 44wk90 mg SC q8w
responder rate · % of participants
NCT01369355 · Phase 3 · converted to % from 68 participants as posted
show 23 more results
66.7% (n=78) vs 45.6% (n=79) placebo @ 44wk*90 mg SC q8w
NCT01369355 · Phase 3 · converted to % from 52 participants as posted
41.1% (n=56) vs 26.2% (n=61) placebo @ 44wk*90 mg SC q8w
NCT01369355 · Phase 3 · converted to % from 23 participants as posted
41.7% (n=72) vs 27.4% (n=73) placebo @ 22wk*90 mg SC
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
24% (n=25) vs 23.1% (n=26) placebo @ 8wk*90 mg SC
NCT00265122 · Phase 2 · registry result, not featured evidence · converted to % from 6 participants as posted
15.9% (n=245) vs 7.3% (n=247) placebo @ 8wk*130 mg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 39 participants as posted
30.6% (n=209) vs 19.6% (n=209) placebo @ 8wk*130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 64 participants as posted
48.8% (n=129) vs 35.9% (n=131) placebo @ 44wk*90 mg SC Q12W
NCT01369355 · Phase 3 · converted to % from 63 participants as posted
56.4% (n=78) vs 45.6% (n=79) placebo @ 44wk*90 mg SC Q12W
NCT01369355 · Phase 3 · converted to % from 44 participants as posted
38.6% (n=57) vs 26.2% (n=61) placebo @ 44wk*90 mg SC Q12W
NCT01369355 · Phase 3 · converted to % from 22 participants as posted
12.2% (n=131) vs 10.6% (n=132) placebo @ 6wk*6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
18.3% (n=131) vs 10.6% (n=132) placebo @ 8wk*6 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted
26.9% (n=26) vs 23.1% (n=26) placebo @ 8wk*4.5 mg/kg IV
NCT00265122 · Phase 2 · registry result, not featured evidence · converted to % from 7 participants as posted
15.9% (n=132) vs 10.6% (n=132) placebo @ 6wk*3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
18.2% (n=132) vs 10.6% (n=132) placebo @ 8wk*3 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted
16% (n=131) vs 10.6% (n=132) placebo @ 6wk*1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
17.6% (n=131) vs 10.6% (n=132) placebo @ 8wk*1 mg/kg IV
NCT00771667 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
20.9% (n=249) vs 7.3% (n=247) placebo @ 8wk*~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 52 participants as posted
40.2% (n=209) vs 19.6% (n=209) placebo @ 8wk*~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 84 participants as posted
35.8% (n=53) vs 38.9% (n=54) Ustekinumab @ 8wk*q4w
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
30.8% (n=52) vs 36% (n=50) Ustekinumab @ 48wk*q4w
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 16 Participants as posted
30% (n=50) vs 14.6% (n=48) placebo @ 12wkLow Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
18.4% (n=49) vs 14.6% (n=48) placebo @ 12wkMiddle Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
22.4% (n=49) vs 14.6% (n=48) placebo @ 12wkHigh Dose
NCT02877134 · Phase 2 · registry result, not featured evidence
CDA 70 46.1% (n=245) vs 30.4% (n=247) placebo @ 6wk130 mg
responder rate · % of participants
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 113 participants as posted
show 3 more results
38.4% (n=245) vs 27.1% (n=247) placebo @ 3wk*130 mg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 94 participants as posted
43.8% (n=249) vs 30.4% (n=247) placebo @ 6wk*~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 109 participants as posted
40.6% (n=249) vs 27.1% (n=247) placebo @ 3wk*~6 mg/kg
NCT01369329 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 101 participants as posted
CDAI ≥ 70 58.9% (n=209) vs 38.8% (n=209) placebo @ 6wk130 mg
responder rate · % of participants
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 123 participants as posted
show 3 more results
49.3% (n=209) vs 31.6% (n=209) placebo @ 3wk*130 mg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 103 participants as posted
64.6% (n=209) vs 38.8% (n=209) placebo @ 6wk*~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 135 participants as posted
50.7% (n=209) vs 31.6% (n=209) placebo @ 3wk*~6 mg/kg
NCT01369342 · Phase 3 · Crohn's Disease · phase 3 · converted to % from 106 participants as posted
Corticosteroid-free Clinical Remission 46.9% (n=128) vs 29.8% (n=131) placebo @ 44wk90 mg SC q8w
responder rate · % of participants
NCT01369355 · Phase 3 · converted to % from 60 participants as posted
show 1 more result
42.6% (n=129) vs 29.8% (n=131) placebo @ 44wk*90 mg SC Q12W
NCT01369355 · Phase 3 · converted to % from 55 participants as posted
Steroid Free Clinical Remission and Fecal Calprotectin Lt250 14.8% (n=54) vs 18.5% (n=54) Ustekinumab @ 48wkq4w
event count · % of participants
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 8 Participants as posted
Complete Endoscopic Remission 7.8% (n=51) vs 6% (n=50) Ustekinumab @ 48wkq4w
responder rate · % of participants
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 4 Participants as posted
Endoscopic Remission 29.4% (n=51) vs 16% (n=50) Ustekinumab @ 48wkq4w
responder rate · % of participants
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 15 Participants as posted
Endoscopic 23.5% (n=51) vs 16% (n=50) Ustekinumab @ 48wkq4w
responder rate · % of participants
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 12 Participants as posted
Biomarker Remission 36% (n=50) vs 26% (n=50) Ustekinumab @ 48wkq4w
responder rate · % of participants
NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 18 Participants as posted
CDAI 49.1% (n=108) @ 16wkIV re-induction
responder rate · % of participants
No placebo or comparator arm
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
37.4% (n=107) @ 16wkq8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
51.9% (n=108) @ 8wkIV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
44.9% (n=107) @ 8wkq8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
47.2% (n=108) @ 24wkIV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
39.3% (n=107) @ 24wkq8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
84.5% (n=219) @ 16wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
89.6% (n=221) @ 16wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
68% (n=219) @ 48wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
77.8% (n=221) @ 48wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Remission 33.3% (n=108) @ 16wkIV re-induction
responder rate · % of participants
No placebo or comparator arm
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
show 13 more results
27.1% (n=107) @ 16wkq8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
35.2% (n=108) @ 8wkIV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
29% (n=107) @ 8wkq8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
37% (n=108) @ 24wkIV re-induction
NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3
27.1% (n=107) @ 24wkq8w SC maintenance
NCT03782376 · Phase 3 · Crohn's Disease · phase 3
72.1% (n=219) @ 16wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
74.2% (n=221) @ 16wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
61.6% (n=219) @ 48wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
69.7% (n=221) @ 48wk
NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3
46.5% (n=101) @ 8wkIV
NCT04673357 · Phase 3
48.8% (n=41) @ 52wkSC q8w
NCT04673357 · Phase 3
59.1% (n=44) @ 52wkSC q12w
NCT04673357 · Phase 3
45.5% (n=101) @ 6wkIV
NCT04673357 · Phase 3

+ 23 further endpoints in the CSV export.

Psoriasis

Shared mechanism: IL-12 p40 · full Psoriasis pipeline

ustekinumab · Stelara

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT00307437 · Phase 3 · completed

This was a large (1,230-patient), randomized, blinded, placebo-controlled trial with a validated skin-clearance measure (PASI 75) as its primary endpoint, and both ustekinumab doses beat placebo by a wide, statistically significant margin (p<0.001).

Next expected readout: December 2026 · NCT05270733 (registry estimate)

Reported efficacy

Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12 (Week 0 to Week 12): PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo. (met)

Result source: NCT00307437

ustekinumab-hmny (Starjemza)

Marketed by Bio-Thera Solutions and partners

Approved in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointustekinumabustekinumab-hmny (Starjemza)
PASI 7575.7% vs 3.7%+72 vs placebo90 mg · wk 12 · n 411NCT00307437
18 other results
  • 66.4% vs 3.1% 90 mg · wk 12 · n 256 · Phase 3 · primary NCT00267969
  • 66.7% vs 3.7% 45 mg · wk 12 · n 409 · Phase 3 · primary NCT00307437
  • 67.1% vs 3.1% 45 mg · wk 12 · n 255 · Phase 3 · primary NCT00267969
  • 67.7% vs 6.5% 90 mg · wk 12 · n 62 · Phase 3 · primary NCT00723528
  • 82.5% vs 11.1% 45 mg · wk 12 · n 160 · Phase 3 · primary NCT01008995
  • 59.4% vs 6.5% 45 mg · wk 12 · n 64 · Phase 3 · primary NCT00723528
  • 67.2% vs 5% 45 mg · wk 12 · n 61 · Phase 3 · primary NCT00747344
  • 73.8% vs 56.8% 90 mg · wk 12 · n 347 · Phase 3 · primary NCT00454584
  • 67.5% vs 56.8% 45 mg · wk 12 · n 209 · Phase 3 · primary NCT00454584
  • 78.4% vs 10.8% Half-Standard Dosage · wk 12 · n 37 · Phase 3 · secondary NCT01090427
  • 80.6% vs 10.8% Standard Dosage · wk 12 · n 36 · Phase 3 · secondary NCT01090427
  • 80.8% vs 80.1% wk 16 · n 281 · Phase 3 · secondary NCT04607980
  • 69.8% vs 70.2% wk 12 · n 281 · Phase 3 · secondary NCT04607980
  • 11.4% vs 10.3% wk 4 · n 281 · Phase 3 · secondary NCT04607980
  • 59.4% vs 1.6% 90 mg · wk 12 · n 64 · Phase 2 · primary NCT00320216
  • 81.3% vs 1.6% 90 mg weekly for 4 weeks · wk 12 · n 64 · Phase 2 · primary NCT00320216
  • 51.6% vs 1.6% 45 mg · wk 12 · n 64 · Phase 2 · primary NCT00320216
  • 67.2% vs 1.6% 45 mg weekly for 4 weeks · wk 12 · n 64 · Phase 2 · primary NCT00320216
—Not posted · NCT04728360
PASI 9054.1% vs 5.4%+48.7 vs placeboHalf-Standard Dosage · wk 12 · n 37NCT01090427
3 other results
  • 61.1% vs 5.4% Standard Dosage · wk 12 · n 36 · Phase 3 · secondary NCT01090427
  • 44.7% vs 23.1% 90 mg · wk 12 · n 347 · Phase 3 · secondary NCT00454584
  • 36.4% vs 23.1% 45 mg · wk 12 · n 209 · Phase 3 · secondary NCT00454584
—Not posted · NCT04728360
PASI 10029.9% vs 26.2%vs Ustekinumabwk 16 · n 281NCT04607980
2 other results
  • 20.6% vs 19.1% wk 12 · n 281 · Phase 3 · secondary NCT04607980
  • 0.4% vs 0.7% wk 4 · n 281 · Phase 3 · secondary NCT04607980
—Not posted · NCT04728360
sPGA 0/167.6% vs 5.4%+62.2 vs placeboHalf-Standard Dosage · wk 12 · n 37NCT01090427
10 other results
  • 69.4% vs 5.4% Standard Dosage · wk 12 · n 36 · Phase 3 · primary NCT01090427
  • 73% vs 4.4% 90 mg · wk 12 · n 411 · Phase 3 · secondary NCT00307437
  • 60.9% vs 3.9% 90 mg · wk 12 · n 256 · Phase 3 · secondary NCT00267969
  • 67.7% vs 4.4% 45 mg · wk 12 · n 409 · Phase 3 · secondary NCT00307437
  • 59.2% vs 3.9% 45 mg · wk 12 · n 255 · Phase 3 · secondary NCT00267969
  • 78.8% vs 14.8% 45 mg · wk 12 · n 160 · Phase 3 · secondary NCT01008995
  • 70.5% vs 8.3% 45 mg · wk 12 · n 61 · Phase 3 · secondary NCT00747344
  • 70.6% vs 49% 90 mg · wk 12 · n 347 · Phase 3 · secondary NCT00454584
  • 65.1% vs 49% 45 mg · wk 12 · n 209 · Phase 3 · secondary NCT00454584
  • 55.2% vs 52.8% wk 12 · n 281 · Phase 3 · secondary NCT04607980
—Not posted · NCT04728360
DLQI, change-9 vs -0.5−8.5 vs placebo90 mg · wk 12 · n 402NCT00307437
7 other results
  • -7 vs 0 90 mg · wk 12 · n 249 · Phase 3 · secondary NCT00267969
  • -8 vs -0.5 45 mg · wk 12 · n 401 · Phase 3 · secondary NCT00307437
  • -6 vs 0 45 mg · wk 12 · n 254 · Phase 3 · secondary NCT00267969
  • -7.4 vs -0.3 90 mg · wk 12 · n 61 · Phase 3 · secondary NCT00723528
  • -9.3 vs -1.9 45 mg · wk 12 · n 158 · Phase 3 · secondary NCT01008995
  • -8 vs -0.3 45 mg · wk 12 · n 62 · Phase 3 · secondary NCT00723528
  • -11.2 vs -0.5 45 mg · wk 12 · n 61 · Phase 3 · secondary NCT00747344
—Not posted · NCT04728360

PASI 75

ustekinumab
75.7% vs 3.7%+72 vs placebo90 mg · wk 12 · n 411NCT00307437
18 other results
  • 66.4% vs 3.1% 90 mg · wk 12 · n 256 · Phase 3 · primary NCT00267969
  • 66.7% vs 3.7% 45 mg · wk 12 · n 409 · Phase 3 · primary NCT00307437
  • 67.1% vs 3.1% 45 mg · wk 12 · n 255 · Phase 3 · primary NCT00267969
  • 67.7% vs 6.5% 90 mg · wk 12 · n 62 · Phase 3 · primary NCT00723528
  • 82.5% vs 11.1% 45 mg · wk 12 · n 160 · Phase 3 · primary NCT01008995
  • 59.4% vs 6.5% 45 mg · wk 12 · n 64 · Phase 3 · primary NCT00723528
  • 67.2% vs 5% 45 mg · wk 12 · n 61 · Phase 3 · primary NCT00747344
  • 73.8% vs 56.8% 90 mg · wk 12 · n 347 · Phase 3 · primary NCT00454584
  • 67.5% vs 56.8% 45 mg · wk 12 · n 209 · Phase 3 · primary NCT00454584
  • 78.4% vs 10.8% Half-Standard Dosage · wk 12 · n 37 · Phase 3 · secondary NCT01090427
  • 80.6% vs 10.8% Standard Dosage · wk 12 · n 36 · Phase 3 · secondary NCT01090427
  • 80.8% vs 80.1% wk 16 · n 281 · Phase 3 · secondary NCT04607980
  • 69.8% vs 70.2% wk 12 · n 281 · Phase 3 · secondary NCT04607980
  • 11.4% vs 10.3% wk 4 · n 281 · Phase 3 · secondary NCT04607980
  • 59.4% vs 1.6% 90 mg · wk 12 · n 64 · Phase 2 · primary NCT00320216
  • 81.3% vs 1.6% 90 mg weekly for 4 weeks · wk 12 · n 64 · Phase 2 · primary NCT00320216
  • 51.6% vs 1.6% 45 mg · wk 12 · n 64 · Phase 2 · primary NCT00320216
  • 67.2% vs 1.6% 45 mg weekly for 4 weeks · wk 12 · n 64 · Phase 2 · primary NCT00320216
ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360

PASI 90

ustekinumab
54.1% vs 5.4%+48.7 vs placeboHalf-Standard Dosage · wk 12 · n 37NCT01090427
3 other results
  • 61.1% vs 5.4% Standard Dosage · wk 12 · n 36 · Phase 3 · secondary NCT01090427
  • 44.7% vs 23.1% 90 mg · wk 12 · n 347 · Phase 3 · secondary NCT00454584
  • 36.4% vs 23.1% 45 mg · wk 12 · n 209 · Phase 3 · secondary NCT00454584
ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360

PASI 100

ustekinumab
29.9% vs 26.2%vs Ustekinumabwk 16 · n 281NCT04607980
2 other results
  • 20.6% vs 19.1% wk 12 · n 281 · Phase 3 · secondary NCT04607980
  • 0.4% vs 0.7% wk 4 · n 281 · Phase 3 · secondary NCT04607980
ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360

sPGA 0/1

ustekinumab
67.6% vs 5.4%+62.2 vs placeboHalf-Standard Dosage · wk 12 · n 37NCT01090427
10 other results
  • 69.4% vs 5.4% Standard Dosage · wk 12 · n 36 · Phase 3 · primary NCT01090427
  • 73% vs 4.4% 90 mg · wk 12 · n 411 · Phase 3 · secondary NCT00307437
  • 60.9% vs 3.9% 90 mg · wk 12 · n 256 · Phase 3 · secondary NCT00267969
  • 67.7% vs 4.4% 45 mg · wk 12 · n 409 · Phase 3 · secondary NCT00307437
  • 59.2% vs 3.9% 45 mg · wk 12 · n 255 · Phase 3 · secondary NCT00267969
  • 78.8% vs 14.8% 45 mg · wk 12 · n 160 · Phase 3 · secondary NCT01008995
  • 70.5% vs 8.3% 45 mg · wk 12 · n 61 · Phase 3 · secondary NCT00747344
  • 70.6% vs 49% 90 mg · wk 12 · n 347 · Phase 3 · secondary NCT00454584
  • 65.1% vs 49% 45 mg · wk 12 · n 209 · Phase 3 · secondary NCT00454584
  • 55.2% vs 52.8% wk 12 · n 281 · Phase 3 · secondary NCT04607980
ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360

DLQI, change

ustekinumab
-9 vs -0.5−8.5 vs placebo90 mg · wk 12 · n 402NCT00307437
7 other results
  • -7 vs 0 90 mg · wk 12 · n 249 · Phase 3 · secondary NCT00267969
  • -8 vs -0.5 45 mg · wk 12 · n 401 · Phase 3 · secondary NCT00307437
  • -6 vs 0 45 mg · wk 12 · n 254 · Phase 3 · secondary NCT00267969
  • -7.4 vs -0.3 90 mg · wk 12 · n 61 · Phase 3 · secondary NCT00723528
  • -9.3 vs -1.9 45 mg · wk 12 · n 158 · Phase 3 · secondary NCT01008995
  • -8 vs -0.3 45 mg · wk 12 · n 62 · Phase 3 · secondary NCT00723528
  • -11.2 vs -0.5 45 mg · wk 12 · n 61 · Phase 3 · secondary NCT00747344
ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ustekinumab-hmny (Starjemza): no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ustekinumab: 4 of 4 rows · ustekinumab-hmny (Starjemza): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricustekinumab
Dropout rate
—90 mga
NCT00307437 · Phase 3
show 44 more results
2.2%90 mg
NCT00307437 · Phase 3
—45 mg
NCT00307437 · Phase 3
1.5%45 mg
NCT00307437 · Phase 3
—90 mg
NCT00267969 · Phase 3
4.3%90 mg
NCT00267969 · Phase 3
—45 mg
NCT00267969 · Phase 3
0.4%45 mg
NCT00267969 · Phase 3
—
NCT02187172 · Phase 4 · registry result, not featured evidence
11.1%
NCT01511315 · Phase 4 · registry result, not featured evidence
9.8%
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
—
NCT04435600 · Phase 3 · registry result, not featured evidence
—Post Week 28: ABP 654 / ABP 654
NCT04607980 · Phase 3 · registry result, not featured evidence
—Post Week 28: ABP 654 Dose Intensi
NCT04607980 · Phase 3 · registry result, not featured evidence
—Through Week 28: ABP 654
NCT04607980 · Phase 3 · registry result, not featured evidence
4.3%Treatment Group A (ABP 654)
NCT04607980 · Phase 3 · registry result, not featured evidence
—Ustekinumab Standard Dosage (Long-
NCT02698475 · Phase 3 · registry result, not featured evidence
—Ustekinumab Standard Dosage (Main
NCT02698475 · Phase 3 · registry result, not featured evidence
—
NCT02203032 · Phase 3 · registry result, not featured evidence
—q12w
NCT01550744 · Phase 3 · registry result, not featured evidence
—subject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
—Half-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
0%Half-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
—Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
0%Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
1.9%45 mg
NCT01008995 · Phase 3 · registry result, not featured evidence
—90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
6.5%90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
—45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
0%45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
—45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
6.6%45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
—90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
1.4%90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
—45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
3.8%45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
—90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
9.4%90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
—90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
9.4%90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
—45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
15.6%45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
—45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
4.7%45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
14.3%
NCT01090063 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—90 mga
NCT00307437 · Phase 3
show 44 more results
1.2%90 mg
NCT00307437 · Phase 3
—45 mg
NCT00307437 · Phase 3
0.5%45 mg
NCT00307437 · Phase 3
—90 mg
NCT00267969 · Phase 3
0.8%90 mg
NCT00267969 · Phase 3
—45 mg
NCT00267969 · Phase 3
0%45 mg
NCT00267969 · Phase 3
—
NCT02187172 · Phase 4 · registry result, not featured evidence
—
NCT01511315 · Phase 4 · registry result, not featured evidence
0.8%
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
—
NCT04435600 · Phase 3 · registry result, not featured evidence
—Post Week 28: ABP 654 / ABP 654
NCT04607980 · Phase 3 · registry result, not featured evidence
—Post Week 28: ABP 654 Dose Intensi
NCT04607980 · Phase 3 · registry result, not featured evidence
—Through Week 28: ABP 654
NCT04607980 · Phase 3 · registry result, not featured evidence
1.1%Treatment Group A (ABP 654)
NCT04607980 · Phase 3 · registry result, not featured evidence
—Ustekinumab Standard Dosage (Long-
NCT02698475 · Phase 3 · registry result, not featured evidence
—Ustekinumab Standard Dosage (Main
NCT02698475 · Phase 3 · registry result, not featured evidence
—
NCT02203032 · Phase 3 · registry result, not featured evidence
—q12w
NCT01550744 · Phase 3 · registry result, not featured evidence
—subject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
—Half-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
—Half-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
—Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
—Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
1.3%45 mg
NCT01008995 · Phase 3 · registry result, not featured evidence
—90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
1.6%90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
—45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
0%45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
—45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
0%45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
—90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
0.3%90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
—45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
1%45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
—90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
0%90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
—90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
3.1%90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
—45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
9.4%45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
—45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
3.1%45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
—
NCT01090063 · Phase na · registry result, not featured evidence
Serious AEs
17.8%90 mga
NCT00307437 · Phase 3
show 44 more results
1.2%90 mg
NCT00307437 · Phase 3
19.9%45 mg
NCT00307437 · Phase 3
2%45 mg
NCT00307437 · Phase 3
13.1%90 mg
NCT00267969 · Phase 3
1.6%90 mg
NCT00267969 · Phase 3
14.9%45 mg
NCT00267969 · Phase 3
0.8%45 mg
NCT00267969 · Phase 3
0%
NCT02187172 · Phase 4 · registry result, not featured evidence
0%
NCT01511315 · Phase 4 · registry result, not featured evidence
8.2%
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04435600 · Phase 3 · registry result, not featured evidence
0.4%Post Week 28: ABP 654 / ABP 654
NCT04607980 · Phase 3 · registry result, not featured evidence
4%Post Week 28: ABP 654 Dose Intensi
NCT04607980 · Phase 3 · registry result, not featured evidence
2.5%Through Week 28: ABP 654
NCT04607980 · Phase 3 · registry result, not featured evidence
—Treatment Group A (ABP 654)
NCT04607980 · Phase 3 · registry result, not featured evidence
3.6%Ustekinumab Standard Dosage (Long-
NCT02698475 · Phase 3 · registry result, not featured evidence
6.8%Ustekinumab Standard Dosage (Main
NCT02698475 · Phase 3 · registry result, not featured evidence
4.5%
NCT02203032 · Phase 3 · registry result, not featured evidence
9.2%q12w
NCT01550744 · Phase 3 · registry result, not featured evidence
7%subject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
13.5%Half-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
2.7%Half-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
2.8%Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
0%Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
0.6%45 mg
NCT01008995 · Phase 3 · registry result, not featured evidence
6.5%90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
4.8%90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
7.8%45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
0%45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
3.4%45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
0%45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
6.4%90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
1.2%90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
6.4%45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
1.9%45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence
3.3%90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
1.6%90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
6.5%90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
4.8%90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
4.8%45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence
0%45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
3.2%45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence
0%
NCT01090063 · Phase na · registry result, not featured evidence
Most frequent reported AEs
90 mga
nasopharyngitis 35% (placebo 7.1%)
upper respiratory tract infection 27.1% (placebo 3.4%)
arthralgia 14.7% (placebo 2.9%)
NCT00307437 · Phase 3
show 42 more results
90 mg
nasopharyngitis 6.8% (placebo 7.1%)
headache 4.6% (placebo 4.1%)
upper respiratory tract infection 2.9% (placebo 3.4%)
NCT00307437 · Phase 3
45 mg
nasopharyngitis 33.7% (placebo 7.1%)
upper respiratory tract infection 27.5% (placebo 3.4%)
back pain 12.5% (placebo 1.7%)
NCT00307437 · Phase 3
45 mg
nasopharyngitis 7.3% (placebo 7.1%)
headache 4.6% (placebo 4.1%)
upper respiratory tract infection 4.4% (placebo 3.4%)
NCT00307437 · Phase 3
90 mg
upper respiratory tract infection 30.7% (placebo 6.3%)
upper respiratory tract infection 30.7% (placebo 6.3%)
nasopharyngitis 29.9% (placebo 8.6%)
NCT00267969 · Phase 3
90 mg
nasopharyngitis 8.2% (placebo 8.6%)
upper respiratory tract infection 6.3% (placebo 6.3%)
upper respiratory tract infection 6.3% (placebo 6.3%)
NCT00267969 · Phase 3
45 mg
upper respiratory tract infection 32.2% (placebo 6.3%)
upper respiratory tract infection 32.2% (placebo 6.3%)
nasopharyngitis 27.5% (placebo 8.6%)
NCT00267969 · Phase 3
45 mg
nasopharyngitis 10.2% (placebo 8.6%)
upper respiratory tract infection 7.1% (placebo 6.3%)
upper respiratory tract infection 7.1% (placebo 6.3%)
NCT00267969 · Phase 3
upper respiratory infection 50% (placebo 21.1%)
common cold 27.3% (placebo 10.5%)
anxiety 9.1% (placebo 0%)
NCT02187172 · Phase 4 · registry result, not featured evidence
nasopharyngitis 23.3%
headache 13.5%
arthralgia 11%
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 14.3% (placebo 9.5%)
headache 10.7% (placebo 4.8%)
covid-19 7.1% (placebo 9.5%)
NCT04435600 · Phase 3 · registry result, not featured evidence
covid-19 9.3%
nasopharyngitis 3.6%
upper respiratory tract infection 2.4%
NCT04607980 · Phase 3 · registry result, not featured evidence
covid-19 20%
nasopharyngitis 8%
proteinuria 8%
NCT04607980 · Phase 3 · registry result, not featured evidence
nasopharyngitis 2.5%
covid-19 2.1%
upper respiratory tract infection 2.1%
NCT04607980 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28.6%
arthralgia 10.7%
cough 10.7%
NCT02698475 · Phase 3 · registry result, not featured evidence
nasopharyngitis 25%
injection site erythema 13.6%
pharyngitis 13.6%
NCT02698475 · Phase 3 · registry result, not featured evidence
nasopharyngitis 17.3%
upper respiratory tract infection 8.3%
NCT02203032 · Phase 3 · registry result, not featured evidence
q12w
upper respiratory tract infection 27.6%
nasopharyngitis 9.2%
arthralgia 7.9%
NCT01550744 · Phase 3 · registry result, not featured evidence
subject-tailored fixed-interval
upper respiratory tract infection 19.5%
nasopharyngitis 15.6%
sinusitis 5.6%
NCT01550744 · Phase 3 · registry result, not featured evidence
Half-Standard Dosage
nasopharyngitis 29.7% (placebo 27%)
headache 24.3% (placebo 5.4%)
upper respiratory tract infection 10.8% (placebo 5.4%)
NCT01090427 · Phase 3 · registry result, not featured evidence
Half-Standard Dosage
nasopharyngitis 13.5% (placebo 27%)
headache 10.8% (placebo 5.4%)
pharyngitis 8.1% (placebo 0%)
NCT01090427 · Phase 3 · registry result, not featured evidence
Standard Dosage
nasopharyngitis 30.6% (placebo 27%)
dysmenorrhoea 8.3% (placebo 0%)
upper respiratory tract infection 8.3% (placebo 5.4%)
NCT01090427 · Phase 3 · registry result, not featured evidence
Standard Dosage
headache 8.3% (placebo 5.4%)
upper respiratory tract infection 8.3% (placebo 5.4%)
diarrhoea 5.6% (placebo 0%)
NCT01090427 · Phase 3 · registry result, not featured evidence
45 mg
nasopharyngitis 11.9% (placebo 8.1%)
upper respiratory tract infection 5.6% (placebo 5%)
NCT01008995 · Phase 3 · registry result, not featured evidence
90 mg
nasopharyngitis 46.8% (placebo 9.4%)
blood creatine phosphokinase increased 19.4% (placebo 3.1%)
seasonal allergy 14.5% (placebo 0%)
NCT00723528 · Phase 3 · registry result, not featured evidence
90 mg
nasopharyngitis 16.1% (placebo 9.4%)
eosinophil count increased 6.5% (placebo 3.1%)
blood uric acid increased 3.2% (placebo 0%)
NCT00723528 · Phase 3 · registry result, not featured evidence
45 mg
nasopharyngitis 54.7% (placebo 9.4%)
blood triglycerides increased 20.3% (placebo 3.1%)
blood creatine phosphokinase increased 17.2% (placebo 3.1%)
NCT00723528 · Phase 3 · registry result, not featured evidence
45 mg
nasopharyngitis 15.6% (placebo 9.4%)
blood triglycerides increased 10.9% (placebo 3.1%)
eosinophil count increased 4.7% (placebo 3.1%)
NCT00723528 · Phase 3 · registry result, not featured evidence
45 mg
nasopharyngitis 13.6% (placebo 5%)
hepatic function abnormal 8.5% (placebo 3.3%)
upper respiratory tract infection 8.5% (placebo 11.7%)
NCT00747344 · Phase 3 · registry result, not featured evidence
45 mg
upper respiratory tract infection 11.5% (placebo 11.7%)
hyperglycaemia 8.2% (placebo 8.3%)
nasopharyngitis 8.2% (placebo 5%)
NCT00747344 · Phase 3 · registry result, not featured evidence
90 mg
nasopharyngitis 18.4%
upper respiratory tract infection 16%
back pain 6.4%
NCT00454584 · Phase 3 · registry result, not featured evidence
90 mg
headache 12.1%
nasopharyngitis 9.8%
upper respiratory tract infection 6.3%
NCT00454584 · Phase 3 · registry result, not featured evidence
45 mg
nasopharyngitis 16.7%
upper respiratory tract infection 14.2%
oropharyngeal pain 5.4%
NCT00454584 · Phase 3 · registry result, not featured evidence
45 mg
headache 14.8%
nasopharyngitis 10%
back pain 6.7%
NCT00454584 · Phase 3 · registry result, not featured evidence
90 mg
upper resp tract infection 14.8% (placebo 20.9%)
injury 8.2% (placebo 6%)
headache 4.9% (placebo 16.4%)
NCT00320216 · Phase 2 · registry result, not featured evidence
90 mg
upper resp tract infection 31.3% (placebo 20.9%)
headache 18.8% (placebo 16.4%)
pain 12.5% (placebo 3%)
NCT00320216 · Phase 2 · registry result, not featured evidence
90 mg weekly for 4 weeks
upper resp tract infection 11.3% (placebo 20.9%)
pain 3.2% (placebo 3%)
headache 1.6% (placebo 16.4%)
NCT00320216 · Phase 2 · registry result, not featured evidence
90 mg weekly for 4 weeks
upper resp tract infection 17.7% (placebo 20.9%)
headache 14.5% (placebo 16.4%)
nausea 6.5% (placebo 4.5%)
NCT00320216 · Phase 2 · registry result, not featured evidence
45 mg
upper resp tract infection 16.7% (placebo 20.9%)
headache 3.3% (placebo 16.4%)
injury 3.3% (placebo 6%)
NCT00320216 · Phase 2 · registry result, not featured evidence
45 mg
upper resp tract infection 25.4% (placebo 20.9%)
headache 19% (placebo 16.4%)
pruritus 9.5% (placebo 3%)
NCT00320216 · Phase 2 · registry result, not featured evidence
45 mg weekly for 4 weeks
upper resp tract infection 8.1% (placebo 20.9%)
sinusitis 6.5% (placebo 4.5%)
injury 4.8% (placebo 6%)
NCT00320216 · Phase 2 · registry result, not featured evidence
45 mg weekly for 4 weeks
upper resp tract infection 14.3% (placebo 20.9%)
pharyngitis 7.9% (placebo 6%)
pruritus 7.9% (placebo 3%)
NCT00320216 · Phase 2 · registry result, not featured evidence
upper respiratory infection 16.7%
acneiform eruption 8.3%
NCT01090063 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ustekinumab

PASI 75 75.7% (n=411) vs 3.7% (n=410) placebo @ 12wk90 mg
responder rate · % of participants
NCT00307437 · Phase 3 · converted to % from 311 Participants as posted
show 29 more results
66.4% (n=256) vs 3.1% (n=255) placebo @ 12wk*90 mg
NCT00267969 · Phase 3 · converted to % from 170 Participants as posted
67.7% (n=62) vs 6.5% (n=31) placebo @ 12wk90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
73.8% (n=347) vs 56.8% (n=347) Etanercept @ 12wk*90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence · converted to % from 256 Participants as posted
59.4% (n=64) vs 1.6% (n=64) placebo @ 12wk*90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
81.3% (n=64) vs 1.6% (n=64) placebo @ 12wk*90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 52 Participants as posted
64.3% (n=28) vs 65.9% (n=44) placebo @ 28wk*90 mg
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
30% (n=10) vs 65.9% (n=44) placebo @ 28wk*90 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
66.7% (n=409) vs 3.7% (n=410) placebo @ 12wk*45 mg
NCT00307437 · Phase 3 · converted to % from 273 Participants as posted
67.1% (n=255) vs 3.1% (n=255) placebo @ 12wk*45 mg
NCT00267969 · Phase 3 · converted to % from 171 Participants as posted
82.5% (n=160) vs 11.1% (n=162) placebo @ 12wk*45 mg
NCT01008995 · Phase 3 · registry result, not featured evidence · converted to % from 132 Participants as posted
59.4% (n=64) vs 6.5% (n=31) placebo @ 12wk45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
67.2% (n=61) vs 5% (n=60) placebo @ 12wk*45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
67.5% (n=209) vs 56.8% (n=347) Etanercept @ 12wk*45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence · converted to % from 141 Participants as posted
51.6% (n=64) vs 1.6% (n=64) placebo @ 12wk*45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
28.6% (n=28) vs 65.9% (n=44) placebo @ 28wk*45 mg
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
67.2% (n=64) vs 1.6% (n=64) placebo @ 12wk*45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 43 Participants as posted
47.1% (n=17) vs 65.9% (n=44) placebo @ 28wk*45 mg weekly for 4 weeks
NCT00320216 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
77.3% (n=22) vs 10.5% (n=19) placebo*
NCT02187172 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
11.4% (n=281) vs 10.3% (n=282) Ustekinumab @ 4wk
NCT04607980 · Phase 3 · registry result, not featured evidence
69.8% (n=281) vs 70.2% (n=282) Ustekinumab @ 12wk
NCT04607980 · Phase 3 · registry result, not featured evidence
80.8% (n=281) vs 80.1% (n=282) Ustekinumab @ 16wk
NCT04607980 · Phase 3 · registry result, not featured evidence
85.8% (n=281) vs 82.3% (n=282) Ustekinumab @ 28wk
NCT04607980 · Phase 3 · registry result, not featured evidence
52% (n=281) vs 55.9% (n=282) Ustekinumab @ 36wk
NCT04607980 · Phase 3 · registry result, not featured evidence
94.7% (n=247) vs 94% (n=116) Ustekinumab @ 40wk
NCT04607980 · Phase 3 · registry result, not featured evidence
48% (n=281) vs 64.7% (n=282) Ustekinumab @ 44wk
NCT04607980 · Phase 3 · registry result, not featured evidence
64% (n=281) vs 58.8% (n=282) Ustekinumab @ 52wk
NCT04607980 · Phase 3 · registry result, not featured evidence
89.5% (n=247) vs 58.8% (n=282) Ustekinumab @ 52wk
NCT04607980 · Phase 3 · registry result, not featured evidence
78.4% (n=37) vs 10.8% (n=37) placebo @ 12wkHalf-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
80.6% (n=36) vs 10.8% (n=37) placebo @ 12wkStandard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
sPGA 0/1 73% (n=411) vs 4.4% (n=410) placebo @ 12wk90 mg
responder rate · % of participants
NCT00307437 · Phase 3 · converted to % from 300 Participants as posted
show 13 more results
60.9% (n=256) vs 3.9% (n=255) placebo @ 12wk*90 mg
NCT00267969 · Phase 3 · converted to % from 156 participants as posted
70.6% (n=347) vs 49% (n=347) Etanercept @ 12wk*90 mg
NCT00454584 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted
67.7% (n=409) vs 4.4% (n=410) placebo @ 12wk*45 mg
NCT00307437 · Phase 3 · converted to % from 277 Participants as posted
59.2% (n=255) vs 3.9% (n=255) placebo @ 12wk*45 mg
NCT00267969 · Phase 3 · converted to % from 151 participants as posted
78.8% (n=160) vs 14.8% (n=162) placebo @ 12wk*45 mg
NCT01008995 · Phase 3 · registry result, not featured evidence · converted to % from 126 Participants as posted
70.5% (n=61) vs 8.3% (n=60) placebo @ 12wk*45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
65.1% (n=209) vs 49% (n=347) Etanercept @ 12wk*45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence · converted to % from 136 Participants as posted
63.6% (n=22) vs 10.5% (n=19) placebo*
NCT02187172 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
55.2% (n=281) vs 52.8% (n=282) Ustekinumab @ 12wk
NCT04607980 · Phase 3 · registry result, not featured evidence
24% (n=281) vs 35.3% (n=282) Ustekinumab @ 52wk
NCT04607980 · Phase 3 · registry result, not featured evidence
71.3% (n=247) vs 35.3% (n=282) Ustekinumab @ 52wk
NCT04607980 · Phase 3 · registry result, not featured evidence
67.6% (n=37) vs 5.4% (n=37) placebo @ 12wkHalf-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
69.4% (n=36) vs 5.4% (n=37) placebo @ 12wkStandard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
DLQI -9 vs -0.5 placebo score @ 12wk90 mg
absolute change · score
NCT00307437 · Phase 3
show 7 more results
-7 vs 0 placebo score @ 12wk90 mg
NCT00267969 · Phase 3
-7.4 vs -0.3 placebo score @ 12wk90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
-8 vs -0.5 placebo score @ 12wk45 mg
NCT00307437 · Phase 3
-6 vs 0 placebo score @ 12wk45 mg
NCT00267969 · Phase 3
-9.3 vs -1.9 placebo score @ 12wk45 mg
NCT01008995 · Phase 3 · registry result, not featured evidence
-8 vs -0.3 placebo score @ 12wk45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
-11.2 vs -0.5 placebo score @ 12wk45 mg
NCT00747344 · Phase 3 · registry result, not featured evidence
PASI 75 Response Maintenance 9.4% (n=32)90 mg every 8 weeks
event count · % of participants
No placebo or comparator arm
NCT00307437 · Phase 3 · converted to % from 3 Participants as posted
show 3 more results
3% (n=33)*90 mg every 12 weeks
NCT00307437 · Phase 3 · converted to % from 1 Participants as posted
0% (n=45)*45mg every 8 weeks
NCT00307437 · Phase 3 · converted to % from 0 Participants as posted
2.1% (n=48)*45mg every 12 weeks
NCT00307437 · Phase 3 · converted to % from 1 Participants as posted
PASI 75 90.6% (n=85) @ 52wk90 mg every 12 weeks
responder rate · % of participants
No placebo or comparator arm
NCT00267969 · Phase 3 · converted to % from 77 participants as posted
show 59 more results
82.36% (n=56) @ 64wk90 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
87% (n=77) @ 52wk*45 mg every 12 weeks
NCT00267969 · Phase 3 · converted to % from 67 participants as posted
78.86% (n=60) @ 64wk45 mg
NCT00723528 · Phase 3 · registry result, not featured evidence
78.1% (n=32) @ 36wk
NCT01511315 · Phase 4 · registry result, not featured evidence
78.1% (n=32) @ 24wk
NCT01511315 · Phase 4 · registry result, not featured evidence
71.9% (n=32) @ 12wk
NCT01511315 · Phase 4 · registry result, not featured evidence
2.5% (n=243) @ 2wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
15.3% (n=243) @ 4wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
62.2% (n=243) @ 12wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
64.6% (n=243) @ 16wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
71.1% (n=243) @ 28wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
72.1% (n=243) @ 40wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
76.9% (n=243) @ 52wk
NCT01059773 · Phase 4 · registry result, not featured evidence · combination
85.7% (n=28) @ 16wk
NCT04435600 · Phase 3 · registry result, not featured evidence
84.1% (n=44) @ 12wk
NCT02698475 · Phase 3 · registry result, not featured evidence
96.1% (n=76) @ 28wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
95.7% (n=302) @ 28wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
92% (n=76) @ 32wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
81.1% (n=302) @ 32wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
93.2% (n=76) @ 36wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
78.8% (n=302) @ 36wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
86.3% (n=76) @ 40wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
77.5% (n=302) @ 40wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
90.1% (n=76) @ 44wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
83.5% (n=302) @ 44wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
89.9% (n=76) @ 48wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
82.9% (n=302) @ 48wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
82.6% (n=76) @ 52wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
84.7% (n=302) @ 52wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
85.3% (n=76) @ 56wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
83.8% (n=302) @ 56wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
91.2% (n=76) @ 60wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
82.8% (n=302) @ 60wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
79.7% (n=76) @ 64wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
83.2% (n=302) @ 64wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
85.5% (n=76) @ 68wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
79.9% (n=302) @ 68wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
83.3% (n=76) @ 72wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
83.6% (n=302) @ 72wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
77.3% (n=76) @ 76wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
79.9% (n=302) @ 76wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
81.5% (n=76) @ 80wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
76.4% (n=302) @ 80wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
84.1% (n=76) @ 84wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
74.8% (n=302) @ 84wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
81.3% (n=76) @ 88wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
78.2% (n=302) @ 88wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
84.4% (n=76) @ 92wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
77.2% (n=302) @ 92wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
82.3% (n=76) @ 96wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
79.1% (n=302) @ 96wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
76.6% (n=76) @ 100wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
75.6% (n=302) @ 100wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
81.5% (n=76) @ 104wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
79.2% (n=302) @ 104wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
82.5% (n=76) @ 108wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
79.9% (n=302) @ 108wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
74.1% (n=76) @ 112wkq12w
NCT01550744 · Phase 3 · registry result, not featured evidence
77.7% (n=302) @ 112wksubject-tailored fixed-interval
NCT01550744 · Phase 3 · registry result, not featured evidence
PASI 90 44.7% (n=347) vs 23.1% (n=347) Etanercept @ 12wk90 mg
responder rate · % of participants
NCT00454584 · Phase 3 · registry result, not featured evidence · converted to % from 155 Participants as posted
show 4 more results
36.4% (n=209) vs 23.1% (n=347) Etanercept @ 12wk*45 mg
NCT00454584 · Phase 3 · registry result, not featured evidence · converted to % from 76 Participants as posted
40.9% (n=22) vs 0% (n=19) placebo*
NCT02187172 · Phase 4 · registry result, not featured evidence · converted to % from 9 Participants as posted
54.1% (n=37) vs 5.4% (n=37) placebo @ 12wkHalf-Standard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
61.1% (n=36) vs 5.4% (n=37) placebo @ 12wkStandard Dosage
NCT01090427 · Phase 3 · registry result, not featured evidence
PGWB 23.97 score @ 36wk
absolute change · score
No placebo or comparator arm
NCT01511315 · Phase 4 · registry result, not featured evidence
show 2 more results
19.97 score @ 24wk
NCT01511315 · Phase 4 · registry result, not featured evidence
18.63 score @ 12wk
NCT01511315 · Phase 4 · registry result, not featured evidence
WPAI Overall Work Impairment -21.6 score @ 36wk
absolute change · score
No placebo or comparator arm
total work productivity impairment
NCT01511315 · Phase 4 · registry result, not featured evidence
WPAI Work Time Missed -4.8 score @ 36wk
absolute change · score
No placebo or comparator arm
Absenteeism
NCT01511315 · Phase 4 · registry result, not featured evidence
WPAI Impairment While Working 18.6 score @ 36wk
absolute change · score
No placebo or comparator arm
Presenteeism
NCT01511315 · Phase 4 · registry result, not featured evidence
WPAI Activity Impairment -26.6 score @ 36wk
absolute change · score
No placebo or comparator arm
total activity impairment
NCT01511315 · Phase 4 · registry result, not featured evidence
PQOL-12 -38.34 score @ 36wk
absolute change · score
No placebo or comparator arm
NCT01511315 · Phase 4 · registry result, not featured evidence
show 2 more results
-43.78 score @ 24wk
NCT01511315 · Phase 4 · registry result, not featured evidence
-40.06 score @ 12wk
NCT01511315 · Phase 4 · registry result, not featured evidence

+ 28 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ustekinumab's landscape · ustekinumab-hmny (Starjemza)'s landscape